At present, there is evidence that highly selective small molecule inhibitors of CDK4 and CDK6, Palbociclib, Ribociclib and Abemaciclib, are effective in the treatment of breast cancer (46), but the therapeutic effect of prostate cancer is not clear. Here, CDK4 is linked to breast cancer.